We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
Read MoreHide Full Article
Omnicell, Inc. (OMCL - Free Report) reported earnings per share of 2 cents in second-quarter 2017, in line with the Zacks Consensus Estimate. Earnings improved from the year-ago loss of 3 cents.
Considering stock-based compensation expenses as a regular one, adjusted earnings per share came in at 19 cents, as compared with earnings of 28 cents in the year-ago quarter.
Revenues in Detail
Revenues during the second quarter increased 20.1% year over year to $180.9 million, surpassing the Zacks Consensus Estimate of $174 million. Revenues also exceeded the company’s guided range of $172 million to $178 million.
According to management, the company witnessed strong customer acceptance and popularity of its new XT Series products and revenue performance was also driven by related ramp-up of the XT Series launch. To be precise, the second quarter revenue strength was driven by XT revenue and IV Solutions.
On a segmental basis, Omnicell’s Automation and Analytics revenues fell 0.2% year over year in the second quarter to $148.4 million.
However, revenues at the Medication Adherence segment rose 33.9% year over year to $32.5 million.
Operational Update
Omnicell's gross profit during the reported quarter was down 0.1% to $77.9 million. Gross margin contracted 200 basis points (bps) to 43.1%. According to the company, the adjusted gross margin in the second quarter was 45.3%, reflecting a contraction of 460 bps year over year.
SG&A expenses in the second quarter declined 1.4% year over year to $63.5 million. Research and development expenses increased 22.6% year over year to $16.9 million. Operating expenses were $80.4 million in the second quarter, up 2.9% year over year.
According to the company, adjusted operating expenses in the quarter totaled $71.1 million, up 4.9% from the year-ago quarter.
Financial Update
Omnicell exited second-quarter 2017 with cash and cash equivalents of $26.9 million, compared with $46.3 million at the end of first-quarter 2017.
2017 Guidance
For full-year 2017, Omnicell expects product bookings in the range of $570–$590 million (unchanged from the earlier forecast). The company also reaffirmed adjusted revenue estimates at the band of $720 million to $740 million and adjusted earnings guidance at $1.22 to $1.34 per share. The Zacks Consensus Estimate for full-year earnings per share is pegged at 29 cents. The Zacks Consensus Estimate for full-year revenues stands at $731.8 million.
The company also issued its third-quarter of 2017 guidance. Management expects adjusted revenue in the band of $188 million to $194 million. Omnicell projects third-quarter 2017 adjusted earnings between 38 cents and 45 cents. The Zacks Consensus Estimate for third-quarter revenues is pegged at $199.0 million and third-quarter earnings per share at 20 cents.
Our Take
Omnicell’s second-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Also, the company is expected to gain in terms of revenues and profits from its recent launches and strategic partnerships.
The company recently launched AcuDose software on XT hardware which allows the Aesynt customers to take full advantage of XT. The company also launched XT Series Automated Supply Dispensing system in late Jul 2017. During the second quarter, the company also launched the controlled substance dispenser, a module-providing secured workflow for dispensing and administration of controlled substance.
However, weak margin is a matter of concern.
Zacks Rank & Key Picks
Omnicell currently has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) . Notably, INSYS Therapeutics and Align Technology sport a Zacks Rank #1 (Strong Buy), while Mesa Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock has gained around 1.7% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 29.5% over the last three months.
Mesa Laboratories has a positive earnings surprise of 2.8% for the last four quarters. The stock has added roughly 16.5% over the last six months.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
Omnicell, Inc. (OMCL - Free Report) reported earnings per share of 2 cents in second-quarter 2017, in line with the Zacks Consensus Estimate. Earnings improved from the year-ago loss of 3 cents.
Considering stock-based compensation expenses as a regular one, adjusted earnings per share came in at 19 cents, as compared with earnings of 28 cents in the year-ago quarter.
Revenues in Detail
Revenues during the second quarter increased 20.1% year over year to $180.9 million, surpassing the Zacks Consensus Estimate of $174 million. Revenues also exceeded the company’s guided range of $172 million to $178 million.
According to management, the company witnessed strong customer acceptance and popularity of its new XT Series products and revenue performance was also driven by related ramp-up of the XT Series launch. To be precise, the second quarter revenue strength was driven by XT revenue and IV Solutions.
Omnicell, Inc. Price, Consensus and EPS Surprise
Omnicell, Inc. Price, Consensus and EPS Surprise | Omnicell, Inc. Quote
On a segmental basis, Omnicell’s Automation and Analytics revenues fell 0.2% year over year in the second quarter to $148.4 million.
However, revenues at the Medication Adherence segment rose 33.9% year over year to $32.5 million.
Operational Update
Omnicell's gross profit during the reported quarter was down 0.1% to $77.9 million. Gross margin contracted 200 basis points (bps) to 43.1%. According to the company, the adjusted gross margin in the second quarter was 45.3%, reflecting a contraction of 460 bps year over year.
SG&A expenses in the second quarter declined 1.4% year over year to $63.5 million. Research and development expenses increased 22.6% year over year to $16.9 million. Operating expenses were $80.4 million in the second quarter, up 2.9% year over year.
According to the company, adjusted operating expenses in the quarter totaled $71.1 million, up 4.9% from the year-ago quarter.
Financial Update
Omnicell exited second-quarter 2017 with cash and cash equivalents of $26.9 million, compared with $46.3 million at the end of first-quarter 2017.
2017 Guidance
For full-year 2017, Omnicell expects product bookings in the range of $570–$590 million (unchanged from the earlier forecast). The company also reaffirmed adjusted revenue estimates at the band of $720 million to $740 million and adjusted earnings guidance at $1.22 to $1.34 per share. The Zacks Consensus Estimate for full-year earnings per share is pegged at 29 cents. The Zacks Consensus Estimate for full-year revenues stands at $731.8 million.
The company also issued its third-quarter of 2017 guidance. Management expects adjusted revenue in the band of $188 million to $194 million. Omnicell projects third-quarter 2017 adjusted earnings between 38 cents and 45 cents. The Zacks Consensus Estimate for third-quarter revenues is pegged at $199.0 million and third-quarter earnings per share at 20 cents.
Our Take
Omnicell’s second-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Also, the company is expected to gain in terms of revenues and profits from its recent launches and strategic partnerships.
The company recently launched AcuDose software on XT hardware which allows the Aesynt customers to take full advantage of XT. The company also launched XT Series Automated Supply Dispensing system in late Jul 2017. During the second quarter, the company also launched the controlled substance dispenser, a module-providing secured workflow for dispensing and administration of controlled substance.
However, weak margin is a matter of concern.
Zacks Rank & Key Picks
Omnicell currently has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) . Notably, INSYS Therapeutics and Align Technology sport a Zacks Rank #1 (Strong Buy), while Mesa Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock has gained around 1.7% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 29.5% over the last three months.
Mesa Laboratories has a positive earnings surprise of 2.8% for the last four quarters. The stock has added roughly 16.5% over the last six months.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>